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Anaplastic astrocytoma (AA, WHO grade III) is, second to Glioblastoma, the most common and most malignant type of adult CNS
tumour. Since survival for patients with AA varies markedly and there are no known useful prognostic or therapy response indicators,
the primary purpose of this study was to examine whether knowledge of the known genetic abnormalities found in AA had any
clinical value. The survival data on 37 carefully sampled AA was correlated with the results of a detailed analysis of the status of nine
genes known to be involved in the development of astrocytic tumours. These included three genes coding for proteins in the p53
pathway (TP53, p14
ARFand MDM2), four in the Rb1 pathway (CDKN2A, CDKN2B, RB1 and CDK4) and PTEN and EGFR. We found
that loss of both wild-type copies of any of the three tumour suppressor genes CDKN2A, CDKN2B and RB1 or gene amplification of
CDK4, disrupting the Rb1 pathway, were associated with shorter survival (P¼0.009). This association was consistent in multivariate
analysis, including adjustment for age (P¼0.013). The findings suggest that analysis of the genes coding for Rb1 pathway components
provides additional prognostic information in AA patients receiving conventional therapy.
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Adult astrocytomas are classified by WHO (Kleihues and Cavanee,
2000) into Diffuse Astrocytoma malignancy grade II (AII),
Anaplastic Astrocytoma malignancy grade III (AA) and Glioblas-
toma malignancy grade IV (GB). Standard treatment of both AA
and GB is surgery followed by radiotherapy. Anaplastic Astro-
cytoma patients have variable survival with a median survival of
approximately 3 years – intermediate between AII (median
approximately 7 years) and GB (8–12 months) (Kleihues and
Cavanee, 2000; Herfarth et al, 2001; Backlund et al, 2003). The
histological criteria for an AA diagnosis are also intermediate
between the AII and the GB, the histological findings in AA
ranging from tumours that may be difficult to separate from an AII
to those that have to be distinguished from a GB. The fact that AA
may develop from an AII or may arise de novo and that both have
a tendency to develop into a GB also provides us with diagnostic
difficulties. Adequate histological sampling is essential to exclude a
GB. As with all astrocytic tumours, young age has been generally
accepted as a positive prognostic factor for AA (Perry et al, 1999;
Smith et al, 2001; Rasheed et al, 2002). However, no dependable
histological criteria have been found to provide accurate
prognostic indicators permitting a subdivision of AA into good
and bad prognostic groups.
More than a dozen genes have been documented as being
aberrant in astrocytic tumours and these abnormalities generally
accumulate in a particular order in the different malignancy
grades. TP53 is the most commonly aberrant gene in AII and AA –
approximately 50% of these tumours have no wild-type TP53 and
a further 10–15% have one mutated and one wild-type allele
(Rasheed et al, 1994; Ichimura et al, 2000; Kato et al, 2000).
Glioblastomas that develop from AII or AA also have frequent
TP53 mutations, while the incidence of TP53 mutations in primary
or de novo GB is lower – around 35% (Watanabe et al, 1996). Yet,
primary GBs show disruption of the p53 pathway at similar levels
to AII and AA due to homozygous deletions of p14
ARF or
amplification and overexpression of MDM2 (Ichimura et al,
2000). The majority of GBs also have genetic abnormalities
disrupting the Rb1 pathway, that is, by one of the following: loss
of wild-type CDKN2A (generally together with loss of wild-type
CDKN2B by homozygous deletion) or loss of wild-type RB1 or
amplification and overexpression of CDK4. In addition, losses of
wild-type PTEN occur in almost one-half of GB and amplification
of EGFR in approximately one-third (Ueki et al, 1996; Rasheed
et al, 1997; Schmidt et al, 1999; Ichimura et al, 2000). Anaplastic
Astrocytoma also occasionally show losses of both wild-type copies
of the three tumour suppressor genes (TSGs) located on 9p,
CDKN2A, CDKN2B, p14
ARF (Ichimura et al, 2000), simultaneously
disrupting both the Rb1 and p53 pathways, as well as loss of both
wild-type copies of the PTEN gene on 10q (Schmidt et al, 1999).
Loss of both wild-type RB1 has not been reported in AA (Ueki
et al, 1996; Ichimura et al, 2000). Amplification of proto-oncogenes
occurs almost exclusively in GB. In AA, CDK4/MDM2 amplifica-
tion is rarely seen and EGFR amplification occurs in o10% of the
cases (Bigner et al, 1988; Ichimura et al, 2000). Thus, AAs as
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sdefined by histological criteria appear to consist of a small fraction
showing genetic changes similar to GB (e.g. loss of wild-type
CDKN2A, CDKN2B, p14
ARF and PTEN; amplification of CDK4 and
EGFR) and a majority showing abnormalities similar to AII (i.e.
loss of wild-type TP53). In AA, the frequency of hemizygous
deletions of significant gene loci is greater than that found in AII,
but less than that found in GB and in most cases the retained allele
is wild type (Schmidt et al, 1994; Nishizaki et al, 1998; Ichimura
et al, 2000).
Attempts to correlate the genetic findings in AA with patient
outcome have to-date not provided any convincing correlations
with survival (Galanis et al, 1998; Olson et al, 1998; James et al,
1999; Smith et al, 2001; Rasheed et al, 2002).
The primary purpose of this study was to explore potential
associations between somatic mutations and survival in a series
of 37 AA, since the identification of genetic prognostic indicators
would be of clinical value. We have studied three genes involved in
the p53 pathway (TP53, MDM2 and p14ARF), four genes involved
in the Rb1 pathway (RB1, CDKN2A, CDKN2B and CDK4), PTEN
and EGFR. With the exception of TP53, all these genes are more
commonly altered in GB than in AA. Clinical data were also
considered and tested for associations with survival and when
appropriate used to adjust for potential confounders. Our findings
suggest that patients with well-sampled tumours fulfilling the
WHO criteria for AA (Kleihues and Cavanee, 2000) having genetic
abnormalities affecting any of the genes coding for the compo-
nents of the Rb1 pathway have a poor outcome.
MATERIALS AND METHODS
Patients and tumour tissue
A total of 37 AA patients operated at the Karolinska Hospital,
Stockholm, or Sahlgrenska University Hospital, Gothenburg
between 1989 and 1994 were included in the study. All tumours
were extensively sampled for histology and were reassessed and
classified as AA according to the histological criteria in the 2000
WHO classification (Kleihues and Cavanee, 2000). End of follow-
up of the patients was set to 1st October 2003, providing a
minimum follow-up time of 10.3 years. The clinical data were
collected from the patient records at the hospitals where they
were treated and/or followed up. The data included age and sex of
the patient, tumour localisation, duration and type of symptoms
before diagnosis, date of operation(s), postoperative radiotherapy
and chemotherapy and date of death. Data were missing from a
maximum of one case for any clinical parameter. All operations
were gross total. Thus, no cases diagnosed on biopsy only were
included. The tumour tissue was particularly well sampled – often
all tissue was processed with adjacent pieces alternatively frozen
for molecular analysis and fixed for histology (up to 15 blocks).
The criteria for an AA diagnosis were strictly according to WHO
(Kleihues and Cavanee, 2000). The tumours were moderately to
highly cellular and the tumour cells showed a high nuclear:cyto-
plasmic ratio, distinct nuclear and cytoplasmic pleomorphism with
coarse nuclear chromatin and mitotic activity. There was no
notable microvascular proliferation and no necrotic foci found
anywhere in the material from any case. All patients gave informed
consent and ethics committee approval for the project was
obtained at all sites.
Genetic analysis
Most of the genetic data on this tumour series has been previously
published (Reifenberger et al, 1994; Ichimura et al, 1996; Schmidt
et al, 1999; Ichimura et al, 2000; Liu et al, 2000). Briefly, tumour
DNA was isolated from tumour pieces histopathologically judged
to contain more than 70% tumour cells. Each tumour was
genetically analysed and compared with the individual patient’s
white blood cell DNA. RB1, CDKN2A, CDKN2B, p14
ARF, TP53 and
PTEN were analysed for deletions and mutations. The allelic status
was assessed by studying paired samples of each patients’ blood
and tumour DNA by either densitometry on Southern blotting
using
32P-labelled gene-specific probes or microsatellite analysis
using
33P-labelled PCR in loci in or around each gene by means of
a PhosphorImager analysis (for details, see (Schmidt et al, 1994;
Ichimura et al, 1996; Schmidt et al, 1999; Ichimura et al, 2000)). In
addition, multiplex PCR was used for assessment of homozygous
deletion of PTEN, as other methods would be complicated by the
pseudogene of PTEN (Schmidt et al, 1999). Mutation screening of
RB1, CDKN2A, CDKN2B, p14
ARF, TP53 and PTEN was carried out
using either single-strand conformational polymorphism (SSCP),
denaturing gradient gel electrophoresis (DGGE) or direct sequen-
cing to identify somatic mutations in retained alleles (Ichimura
et al, 1996; Schmidt et al, 1999; Ichimura et al, 2000) (see Figure 1).
The presence or absence of amplification of the proto-oncogenes
CDK4, MDM2 and EGFR was determined using microsatellite
analysis and Southern blotting with densitometry (Reifenberger
et al, 1994; Ichimura et al, 2000; Liu et al, 2000). The genetic data
were complete. In Table 2 each single patient is presented with an
individual publication number, the same as used in previous
Blood
Tumour
TP53 exon 8  c.824G>T (C275F)  
B T
D17S796
CDKN2A
CDKN2B
(D2S44)
B
Control
TB T AB
C
Figure 1 Genetic analysis of AA18. (A) A Southern blot hybridised with
probes for CDKN2A and CDKN2B showing homozygous deletion of both
genes. The control locus hybridisation (D2S44) on the same blot gives a
clear signal from the tumour lane. (B) Microsatellite analysis at D17S796,
the locus approximately 1.3Mb telomeric to TP53. The densitometric
profile indicates LOH in tumour DNA (arrow). (C) Sequencing of TP53
exon 8. G at position 824 is mutated to T (arrow), resulting in Cys to Phe
missense mutation at codon 275. B, blood DNA; T, tumour DNA.
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spublications (Reifenberger et al, 1994; Schmidt et al, 1994;
Ichimura et al, 1996; Ichimura et al, 1998; Schmidt et al, 1999;
Ichimura et al, 2000; Liu et al, 2000).
Statistical analysis and definitions of genes and pathways
as ‘normal’ or ‘abnormal’
The molecular information was restricted to genetic data. All genes
studied were in each tumour classified as either ‘normal’ or
‘abnormal’. The TSGs (CDKN2A, CDKN2B, RB1, TP53, p14
ARF and
PTEN) were categorised as ‘abnormal’ when there was no wild-type
allele present, either due to homozygous deletion or deletion of
one allele and mutation of the other. A comparison of survival in
cases with all genes categorised as ‘normal’ with those having any
gene(s) categorised as ‘abnormal’ was also carried out.
For the proto-oncogenes (EGFR, CDK4 and MDM2), gene
amplification (as in previous publications defined as a minimum
average of five copies per genome) (Ichimura et al, 2000; Liu et al,
2000) was categorised as ‘abnormal’. Cellular pathways (p53 and
Rb1 pathways) were categorized in a similar manner. A pathway
was classified as ‘abnormal’ if any gene coding for a protein
component of the pathway was classified as ‘abnormal’.
Of the 37 tumours analysed, 25 (68%) were from the patients’
first operation. They are referred to as ‘primary’ cases. A total of 12
patients (32%) had a prior operation and a histological diagnosis
of either AII (six cases) or AA (six cases). The six cases that had a
recurrent AA are referred to as ‘recurrent’ cases, while the six cases
that had progressed from an AII are referred to as ‘progressed’
cases. The starting point for patient follow-up was the date of the
operation from which the tumour tissue used in the genetic
analysis was collected, survival being calculated from this date as
we do not know the genetic status of the tumour removed at earlier
operations. To address the potential bias of including the six
‘recurrent’ patients calculating survival as above, separate,
additional correlation analysis was performed, with survival of
the six ‘recurrent’ patients calculated from the date of their first
AA operation, whenever a statistically significant association with
survival was found.
To study the potential influence of single clinical or genetic
factors on patient survival, univariate analysis using Wilcoxon–
Gehan statistic (Gehan, 1965) was performed, with the patients
divided into two groups, except for the age and duration of
symptoms factors. When analysing age and survival, with age as a
continuous variable, Cox Regression analysis was used. In
multivariate analysis of the genetic factors and survival, Cox
Regression analysis was carried out adjusting for age and whether
the tumour studied was from a ‘primary’ or not (with the patients
divided into two groups: ‘primary’ or ‘recurrent’/‘progressed’). All
statistical analyses were performed using SPSS (Statistical Package
for the Social Sciences) for Windows, release 12.0.1.
RESULTS
Clinical data
In Table 1, the clinical data for all cases are summarised with
median survival and some statistical comparisons. In Table 2, the
patients have been placed in one of three groups: (a) ‘primary’ AA;
(b) ‘progressed’ AA (progressed from A) or (c) ‘recurrent’ AA.
Postoperative survival in the whole series varied from 4 months to
at least 13.9 years with a median of 4.3 years. Nine of the 37
patients were still alive at the end of follow-up, with a minimum
follow-up time of 10.3 years. The fraction of males was
uncommonly small in the series, with a male:female ratio of
1:1.5. There was no significant difference in survival between the
sexes, or between the 33 (89%) patients with supratentorial and the
four (11%) with infratentorial tumours. Seven (28%) of the 25
patients with ‘primary’ AA were alive at the end of follow-up as
well as one (17%) of the six patients from each of the ‘recurrent’
and ‘progressed’ groups. The tumours were equally distributed to
the left and right sides, with the patients with the tumour on the
left side having shorter median survival, but only of borderline
significance (P¼0.078).
The mean age at the operation from which material was
obtained was 38.8 years. The mean age at first diagnosis of AA in
all the 37 patients was 37.3. Dividing all the 37 patients into three
approximately equally large age groups (see Table 1 and Figure 2)
demonstrates that the oldest age group (445 years) had the
shortest median survival (1.8 years), although with a wide range
(220 days to 8.5 years). The association between age and survival
was borderline significant both in univariate analysis of the three
groups (P¼0.096), and in Cox regression analysis with age as a
continuous variable (P¼0.093).
The most common de ´but symptom in all cases indicating the
disease process was epilepsy, described in 65% (24 out of 37) of the
patients. The duration between these presenting symptoms and the
operation for AA ranged in the ‘primary’ cases from a few days to
one patient (AA59) with a history of epilepsy for 6.5 years. As
shown in Table 1, dividing the ‘primary’ cases according to the
duration of symptoms before operation revealed no significant
survival differences.
Table 1 Clinical data, median postoperative survival and statistical
analysis
No. of
cases
Median survival
(years) P-value
Overall postoperative survival
(deceased 28; alive 9)
37 4.3
Age in relation to survival (Cox Regression, with age as a
continuous varaiable; Mean age: 38.8 years
P¼0.093
Age groups (years) (Wilcoxon–Gehan, with patients divided into approximately
equally large groups)
8–30 12 5.7
31–45 14 4.7 P¼0.096
a
46–68 11 1.8
Sex
Female 22 3.9
Male 15 5.6 P¼0.607
a
Localisation
Cerebral 33 4.3
Infratentorial 4 46.2 P¼0.605
a
Side
b
Left 17 2.3
Right 17 6.0 P¼0.078
a
‘Primary’ cases
c 25 5.6
‘Recurrent’ and ‘progressed’
cases
12 2.0 P¼0.113
a,c
Duration of symptoms prior to
operation
d
0–3 months 10 4.0
43–o12 months 7 5.8 P¼0.628
a
12 months – 7 8.5
Postoperative radiotherapy
d
Yes 16 5.1
No 8 6.7 P¼0.100
a
aUnivariate analysis of postoperative survival using Wilcoxon–Gehan.
bThree cases
with mid-line location not included in this analysis.
cFor definitions of ‘primary’,
‘recurrent’ and ‘progressed’ cases, see Material and Methods.
d‘Primary’ cases only
(one missing data).
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sTable 2 Summary of clinical and genetic data
a on all 37 AA. Cases are grouped as ‘primary’, ‘progressed’ and ‘recurrent’ AA (for definitions, see Materials and Methods) and then in subgroups with similar
genetic data, with shortest survival first in each subgroup
Publication
number Male/female
Age
(years)
Tumour
localisation
b
Postoperative
RT (Gy)
Postoperative
chemotherapy
Reoperated
later
Survival
(years) CDKN2A CDKN2B RB1 CDK4 MDM2 TP53 p14
ARF EGFR PTEN
‘Primary’ cases (n¼25; median survival¼5.6 years; mean age: 41 years)
AA15 F 24 Supra Left 54 No 5.8 +/+ +/+ +/+ +/+ +/+ +/  +/+ +/+ +/ 
AA59 F 65 Supra Right 0 No 8.5 +/+ +/+ +/+ +/+ +/+ +/+ +/+ +/+ +/+
AA76 M 26 Infra Central 0 No 410.3 +/+ +/+ +/+ +/+ +/+ +/+ +/+ +/+ +/+
AA34 M 38 Supra Right 54 No 411.1 +/+ +/+ +/+ +/+ +/+ +/+ +/+ +/+ +/+
AA102 F 26 Infra Central 50 No Yes 413.9 +/  +/  +/  +/+ +/+ +/+ +/  +/+ +/ 
AA26 F 67 Supra Left 0 No 0.6 +/+ +/+ +/  +/+ +/+ +/C176Y,
R249S
+/+ +/+ +/ 
AA10 M 47 Supra Right 54 No 0.7 +/  +/  +/  +/+ +/+  /R282W +/  +/+ +/ 
AA65 M 12 Infra Central 0 No 1.1 +/+ +/+ +/  +/+ +/+  /R273H +/+ +/+ +/ 
AA106 F 57 Supra Right nk
c nk
c 1.8 +/+ +/+ +/+ +/+ +/+  /V197G +/+ +/+ +/ 
AA69 F 8 Supra Right 54 Yes Yes 2.7 +/+ +/+ +/+ +/+ +/+ +/R273C +/+ +/+ +/+
AA73 M 62 Supra Left 0 No 3.0 +/  +/  +/+ +/+ +/+  /R273L +/  +/+ +/ 
AA100 F 34 Supra Right 50 No Yes 3.5 +/+ +/+ +/+ +/+ +/+ +/R273C,
T304-305ins
+/+ +/+ +/+
AA101 F 35 Supra Left 50 No 4.3 +/+ +/+ +/  +/+ +/+  /R175H +/+ +/+ +/+
AA61 F 34 Supra Left 54 No 4.6 +/+ +/+ +/  +/+ +/+ +/R273C +/+ +/+ +/+
AA79 M 22 Supra Right 50 No Yes 5.6 +/+ +/+ +/+ +/+ +/+  /W146X +/+ +/+ +/+
AA105 M 50 Supra Right 0 No 6.0 +/+ +/+ +/  +/+ +/+ +/H193R +/+ +/+ +/ 
AA37 M 35 Supra Right 50 Yes Yes 7.9 +/  +/  +/+ +/+ +/+ +/R273H +/  +/+ +/+
AA94 F 68 Supra Right 0 Yes 7.3 +/+ +/+ +/+ +/+ +/+  /R273C +/+ +/+ +/ 
AA57 F 31 Supra Left 0 No 410.3 +/+ +/+ +/+ +/+ +/+  /R110L +/+ +/+ +/+
AA19 M 32 Supra Right 54 No 411.0 +/+ +/+ +/+ +/+ +/+  /E180K +/+ +/+ +/+
AA20 F 40 Supra Left 54 No 411.1 +/+ +/+ +/+ +/+ +/+  /R273C +/+ +/+ +/ 
AA52 F 30 Supra Right 54 No 411.9 +/+ +/+ +/+ +/+ +/+ +/T102del +/+ +/+ +/ 
AA7 F 59 Supra Right 50 Yes 1.3 +/  +/  +/+ +/A +/+ +/+ +/  +/A +/ 
AA93 F 57 Supra Right 52 No Yes 1.5  /   /  +/+ +/+ +/+ +/+  /  +/A +/ 
AA29 F 60 Supra Left 37 No 1.9 +/  +/  +/+ +/+ +/+ +/+ +/  +/+  /X404S
d
‘Progressed’ cases (n¼6; median survival¼2.1 years; mean age: 32 years)
AA104 M 35 Supra Left 54 No Yes 2,3 +/+ +/+ +/+ +/+ +/+ +/+ +/+ +/+ +/ 
AA50 M 42 Supra Left 54 No 9,9 +/+ +/+ +/+ +/+ +/+ +/  +/+ +/+ +/ 
AA3 M 23 Supra Right 50 No 413,4 +/+ +/+ +/+ +/+ +/+  /I254T +/+ +/+ +/+
AA17 F 27 Supra Left 54
e No 0,3 +/  +/  +/+ +/A +/+  /R273C +/  +/+ +/ 
AA18 M 18 Supra Left 54
e No 1,1  /   /  +/  +/+ +/+  /C275F  /  +/+ +/ 
AA86 M 45 Supra Right nk
e Yes 2,0  /N71K +/  +/  +/+ +/+  /K320del  /L86V +/+ +/ 
‘Recurrent’ cases (n¼6; median survival¼1.6 years; mean age: 38 years)
AA81 F 30 Supra Right 0 Yes 411,0 +/+ +/+ +/+ +/+ +/+ +/+ +/+ +/+ +/+
AA2 F 51 Supra Left 50
e No 0,6 +/  +/  +/  +/+ +/+  /R110del +/  +/+ +/+
AA13 F 45 Supra Left 0 No 1,0 +/  +/  +/  +/+ +/+  /K164E +/  +/+ +/+
AA87 M 43 Supra Left 50
e No Yes 1,2  /   /  +/+ +/+ +/+  /R273C  /  +/+ +/ 
AA53 F 18 Infra Left 54 No Yes 2,0  /   /  +/+ +/+ +/+ +/+  /  +/+ +/ 
AA51 F 39 Supra Left 50
e Yes
f Yes 4,7  /   /  +/+ +/+ +/+  /I232T  /  +/+ +/ 
a+/+¼two wild-type alleles ;+/ ¼loss of one allele; mutations of alleles replace ‘ ‘ and are annotated as recommended (Antonarakis, 1998); +/A¼amplification of one allele.
bSupra¼supratentorial location; infra¼infratentorial
location.
cnk¼postoperative therapy not known.
dStop codon mutated leading to a prolonged protein by eight amino acids (SIFFYQEGX according to HUGO).
eRadiotherapy given postoperatively after a previous operation
(nk¼doses not known).
fChemotherapy given postoperatively after a previous operation.
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Molecular DiagnosticsIn the following text, the cases will be referred to in the order
that they appear in Table 2:
The 25 ‘primary’ AA had a median survival of 5.6 years and a
mean age of 41 years. In all, 15 of them received postoperative
radiotherapy (RT) at a total dose of 50–54Gy given in 28–30
fractions over 6 weeks. One patient (AA29) was given a course of
37Gy over 2.5 weeks and survived 1.9 years. Eight patients (AA59,
AA76, AA26, AA65, AA73, AA105, AA94 and AA57) were never
irradiated. In one case (AA106), it was not possible to access the
postoperative notes. As shown in Table 1, the median post-
operative survival of the eight ‘primary’ nonirradiated AA patients
(6.3 years) was slightly, but not significantly, longer than for the 16
irradiated patients (5.1 years). Four of the 25 ‘primary’ AA patients
(AA69, AA37, AA94, AA7) received chemotherapy postoperatively,
one of which received polychemotherapy (AA69). Six of the 25
patients (AA102, AA69, AA100, AA79, AA37 and AA93) were later
reoperated upon due to relapse and three of them (AA69, AA100
and AA93) then had evidence of progression to GB. The average
time to progression in these three cases was 1.9 years.
Six patients had progressed from an AII to an AA (average time
to progression to AA was 4.4 years). Their mean age was 32 years
and median survival following the AA operation was 2.1 years.
Three of them were irradiated after the AA operation (AA104,
AA50 and AA3), while the other three (AA17, AA18 and AA86) had
received postoperative RT after their first operation for AII. AA86
received postoperative chemotherapy and AA104 was reoperated
again after 19 months at which time the tumour had progressed to
a GB. AA3 was still alive at the end of follow-up (survival 413.4
years after AA and 413.8 years after the AII diagnosis).
The six ‘recurrent’ cases had had AA at the first operation and
their mean age at that time was 28.5 years. Median survival,
counted from that first AA operation, was 10.8 years while median
survival from the operation for the recurrence was 1.6 years. Of the
six ‘recurrent’ cases, three (AA2, AA87, AA51) had had post-
operative RT after the first operation. AA53 received RT after the
relapse and two patients (AA81 and AA13) did not receive RT at
any time. AA81 was given postoperative chemotherapy after the
recurrence, while AA51 had received chemotherapy after the first
operation. Three patients (AA51, AA53, AA87) were reoperated a
third time and none showed evidence of progression to GB.
Genetic data
The genetic data for each individual tumour is presented in
Table 2, with mutation nomenclature according to recommenda-
tions of the Nomenclature Working Group whenever applicable
(Antonarakis, 1998). In Table 3, the results of univariate and
multivariate analysis of the potential influence of single genetic
factors on patient survival are given. In these analyses, shorter
median survival was always seen in cases categorised as ‘abnormal’
as compared to those categorised as ‘normal’.
As presented in Table 3, the only single genetic aberration
showing a significant negative association with survival was
CDK4 amplification. The statistical significance was borderline
in univariate analysis (P¼0.058) but significant in multivariate
analysis adjusting for age and whether the tumour was ‘primary’ or
‘recurrent’/‘progressed’ (P¼0.019). Disruption of the Rb1 pathway
was negatively associated with survival in univariate (P¼0.009) as
well as in multivariate analysis (P¼0.013). The survival curves for
the Rb1 pathway groups ‘normal’ and ‘abnormal’ are shown in
Figure 3.
A total of 15 cases (AA15, AA59, AA76, AA34, AA102, AA26,
AA69, AA100, AA61, AA105, AA37, AA52, AA104, AA50, AA81)
with all genes classified as ‘normal’ survived longer than those with
at least one of the genes classified as ‘abnormal’. This was
statistically significant in univariate analysis (P¼0.013).
To avoid bias in including the survival data counting survival
for the six ‘recurrent’ patients with the ‘recurrent’ operation as
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Figure 2 Survival curves in three different age groups: 8–30 years
(n¼12); 31–45 years (n¼14); 46–68 years (n¼11). Univariate analysis:
P¼0.096.
Table 3 Median postoperative survival in all cases with or without any gene or pathway classified as ‘abnormal’ (see Material and Methods). Univariate and
multivariate analysis
CDKN2A CDKN2B RB1 CDK4
Rb1
pathway TP53 p14
ARF MDM2
p53
pathway PTEN EGFR All 9 genes
a
Median survival in years
in ‘normal’ cases
b
5.6 5.4 4.3 4.6 5.8 5.8 5.6 4.3 6.0 4.5 4.6 7.9
(n¼) (31) (32) (37) (35) (29) (19) (31) (37) (17) (36) (35) (15)
Median survival in
years in ‘abnormal’ cases
b
17 1.5 – 0.8 1.4 2.5 1.7 – 2.0 1.9 1.4 1.9
(n¼) (6) (5) (0) (2) (8) (18) (6) (0) (20) (1) (2) (22)
Wilcoxon-Gehan P¼ 0.081 0.112 0.058 0.009 0.165 0.081 0.053 0.540 0.199 0.013
Cox Regression
c P¼ 0.102 0.116 0.019 0.013 0.126 0.102 0.223 0.556 0.139 0.093
aComparing survival of the cases with all nine genes categorised as ‘normal’ with those having at least one of the nine genes categorised as ‘abnormal’.
bFor definitions of gene
abnormalities and pathway abnormalities, see Materials and Methods.
cMultivariate analysis using Cox Regression adjusting for age and whether the tumour studied was from a
‘primary’ or ‘recurrent’/‘progressed’ case.
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statistically significant association between the genetic results and
survival was found. As described in Materials and Methods, this
was done calculating survival for these six cases from the date of
their first AA operation. Similar P-values as those reported above
were seen in each additional univariate and multivariate analysis.
For the main finding, the association between Rb1 pathway and
survival, the P-value in multivariate analysis was 0.014 (compared
to P¼0.013).
DISCUSSION
We have focused exclusively on AA as defined by the latest edition
of the WHO classification of tumours of the nervous system
(Kleihues and Cavanee, 2000). Each tumour was extensively
sampled for histology and no tumours with the histological
characteristics of GB or AII were accepted for inclusion. Each piece
of tissue used for the genetic analysis was histologically
characterised to ensure that tumour tissue was studied. This was
confirmed by the genetic analysis of the tumour tissue which, when
compared with the individual patients’ white blood cell DNA,
showed genetic abnormalities in all cases (e.g. loss of hetero-
zygosity (LOH) at a number of sites in addition to point
mutations) (Ichimura et al, 1998; Miyakawa et al, 2000). The age
range of the patients and the location of the tumours are
comparable to similar studies, while the sex distribution is slightly
unusual showing comparatively high number of female subjects
(Kleihues and Cavanee, 2000). A linear relationship between young
age and longer survival was not possible to demonstrate with the
limited number of patients in this study, but when the patients
were divided up in three equally large groups, the subjects in the
oldest group had the worst and the youngest age group the best
outcome. The survival data overall in this series is in accord with
previous studies (Perry et al, 1999; Herfarth et al, 2001; Lin et al,
2003) showing a huge variation from a few months to more than
13 years, widely overlapping that observed for both AII and GB.
Our minimum follow-up here was 10.3 years, which is necessary
in studies where survival can be long.
In a situation where no curative treatment is available, as is
the case for AA, therapy is often modified individually unless all
patients have been included in a particular clinical trial. Most, but
far from all, patients received postoperative RT of 50–54Gy. This
variation in treatment is further complicated by the ‘recurrent’ and
‘progressed’ tumours, where the patients have received radio-
therapy at their first diagnosis and were therefore not eligible for
further irradiation. In addition, it is not unusual to use cytotoxic
drugs at recurrences.
The primary aim of this study was to test for potential
associations between mutations and survival in a clinically,
histopathologically and genetically well-defined series of AA.
There are few studies of this type where only AA is analysed.
Most studies combine AA with the much more malignant GB
under the terms ‘malignant astrocytomas’ or ‘malignant gliomas’.
The study of Smith et al (2001) analysed AA separately and found
a positive association between TP53 mutation and survival and a
negative association between loss of wild-type PTEN and survival.
They included a large number of AA diagnosed with biopsy only,
making a reliable histological classification more difficult. We did
not find any clear associations between TP53 mutation and
survival in any of the comparisons. Since TP53 mutations can have
a dominant negative effect (Willis et al, 2004), we even performed
an analysis with cases with TP53 mutation and retention of one
wild-type allele coded as ‘abnormal’, and this, too, showed no
association with survival (P¼0.165). It is notable that the
commonest point mutation of TP53 (while differing in base
substitution) occurred at codon 273 in 27% of the tumours
(Table 2). Similar findings have been reported in GB recently
(Ohgaki et al, 2004).
As seen in Table 2, some tumours had loss of one wild-type
allele of some TSGs. In fact, for all studied TSGs, this was relatively
frequent. We generally do not know the biological significance of
TSGs losing only one allele. It may result in lowered molar levels
of the gene product providing a growth advantage. The concept of
haploinsufficiency has been well documented for relatively few
genes, but might be of relevance, for example, CDKN2A and p14
ARF
(see review by Quon and Berns, 2001, and references therein)
(Quon and Berns, 2001). Epigenetic mechanisms, such as
methylation, could also be of importance. Although the sensitivity
of SSCP and DGGE as mutation screening methods for point
mutations is high, we cannot exclude the possibility that we have
missed mutations in single cases, since sequencing analysis was
only performed in cases where abnormalities were detected by
SSCP or DGGE.
Although 22 of 37 AAs had loss of one PTEN allele, only one
(AA29) had lost both wild-type PTEN copies (loss of one copy
and point mutation of the stop codon of the other resulting in the
addition of eight amino acids to the C-terminal). The biological
consequence of this PTEN mutation is unclear as all critical regions
of the protein were wild type. Survival was relatively short in this
case (1.9 years). In a previous study of 129GB, we found that a
combination of aberrations of Rb1 pathway-related genes by loss of
both wild-type alleles of TSGs or amplification of proto-oncogenes
(almost always combined with p53 pathway abnormalities) and loss
of both wild-type copies of PTEN was associated with particularly
poor outcome (Backlund et al, 2003). It is important to note that
none of the AAs here had this genetic profile.
The major finding of the present study is that patients with AA
who have a somatic mutation profile resulting in loss of both wild-
type copies of TSGs or amplification of oncogenes involved in the
Rb1 pathway (as found frequently in GB), have a worse outcome as
compared to AAs without these abnormalities. There was two out
of 25 (8%) ‘primary’ AAs with this type of Rb1 pathway
abnormality. The ‘recurrent’ and ‘progressed’ cases showed this
type of Rb1 pathway abnormality in 50%. TP53 mutations,
generally with loss of the second allele, are much more common
in our cohort of AA (about two-third of all cases regardless of
whether ‘primary’ or ‘recurrent’) than we found in our GB series
(45 out of 129 or 35%) (Backlund et al, 2003), a finding that is in
line with previous reports (Rasheed et al, 1994; Kato et al, 2000).
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Figure 3 Survival curves for cases with loss of both wild-type alleles of
any TSG coding for a component of the Rb1 pathway (CDKN2A, CDKN2B,
RB1) or amplification of CDK4, that is, Rb1 pathway classified as ‘abnormal’
(n¼8; median survival 1.4 years) and cases coded as ‘normal’ (n¼29;
median survival 5.8 years), respectively. Univariate analysis: P¼0.009.
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complex. The numerous statistical tests performed in a retro-
spective study like this have to be interpreted with caution. A
larger series of AA will have to be examined to confirm and
extend these results. New developments are providing the
technologies that will permit high throughput genetic analysis on
larger series of uniformly treated patients. Hopefully, the
findings in this study will stimulate further efforts in this regard
leading to improved analysis of AA, providing clinicians with
important prognostic information and eventually targets for
molecular therapy.
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